Pre-Incorporation · Seeking Partners
Protein therapeutics and clinical
intelligence for CNS disorders.
What We Do
Clinical AI generates data and revenue. That data informs therapeutic protein design. The proteins treat the patients AI identified.
Revenue Engine
AI screening and decision-support tools for neurological and ENT conditions. DBS candidacy assessment, Parkinson's progression prediction, ear disease diagnosis. Revenue through hospital partnerships.
Long-Term Pipeline
De novo design of therapeutic proteins targeting CNS disorders. Uses RFdiffusion, ProteinMPNN, and AlphaFold to create BBB-crossing biologics. The long-term R&D play.
The Flywheel Clinical AI tools identify patients and generate data→ Data informs which protein therapeutics to design→ Proteins treat the patients→ cycle repeats.
Products
Try any of our tools — every one is publicly accessible right now.
AI-assisted ear disease diagnosis from otoscopic images. Upload an image and get an instant screening result.
Try LiveMultimodal deep brain stimulation outcome predictor using multi-source patient data.
Try LiveDBS candidacy screening tool for Parkinson's patients. Determines suitability for deep brain stimulation.
Try LiveProtein-ligand binding affinity prediction. Predicts how strongly a drug binds to its protein target.
Try LiveBlood-brain barrier permeability prediction. Assesses whether compounds can cross the BBB to reach the CNS.
Try LiveWatch how biological complexity
transforms into actionable AI insights.
Strategic Base
A convergence of funding, infrastructure, and policy that makes Korea ideal for AI-driven biotech.
Non-dilutive capital.
Korea allocated ₩3.46 trillion to startups in 2026. Non-dilutive funding through TIPS, K-Startup Grand Challenge, Deep Tech Package.
Potential partners next door.
Samsung Biologics, Celltrion, and 200+ biotech companies form a rich ecosystem for partnerships and talent.
Mentoring and access.
Gachon Cocone School provides startup mentoring, workspace, funding up to ₩150M, and investor access for research-based ventures.
Tailwind from the top.
National priority on AI + bio-health convergence with dedicated government funding tracks.
About
Vision
A world where neurological diseases are detected early and treated with precision-designed protein therapeutics.
Mission
By 2029, we aim to deploy AI screening tools in 50 Korean hospitals and advance 2 novel protein therapeutics into preclinical validation.
The Name Named after the founder's father, Ratan — “jewel” in Punjabi and Hindi. The company carries his name as a tribute and a promise.
Team
Founder
PhD Candidate, Dept. of Life Science, Gachon University
5 deployed AI products. 4 published research papers, 3 under review. Expertise in protein engineering, computational
biology, and AI.
PhD on a fully funded scholarship at Gachon University. M.S. and B.S. in Biotechnology, Shoolini University, India (Top 500 Global University).
Advisor
Dean of Research Affairs, Professor, Gachon University
CEO Lipidomia Co., Ltd. Former Associate Research Scientist at Columbia
University and Cardiovascular Pharmacology Scientist at Pfizer USA. Ph.D./M.S. Rutgers
University, B.S. Korea University.
~100 research papers, 10 patents. Editorial Board Member of Journal of
Biological Chemistry and Journal of Lipid Research.
Head of Business Operations
Master's Candidate, Dept. of Life Science, Gachon University
Korean market entry, grant compliance, and regulatory affairs.
B.S. in Life Sciences, Gachon University.
Evidence & Roadmap
Live today
5
Not prototypes, not roadmap items. Five tools you can open in a browser right now.
Advisor
~100
Prof. Tae-Sik Park — 10 patents. Editorial board, Journal of Biological Chemistry and Journal of Lipid Research.
Live today · by domain
ENT Diagnostics 1
Neurology 2
Drug Discovery 2
Market context · Korea
₩3.46T
Korea's figure, not ours: non-dilutive capital we can compete for, alongside 200+ biotech companies.
Roadmap
2026 Live
Across ENT, neurology and drug discovery — including RATAN-PBind for binding affinity and BBBAI for blood-brain barrier permeability.
Early 2027 Target
Ratan Bio is pre-incorporation today. This has not happened yet.
2029 Target
Target · 2029
50
Korean hospitals running our AI screening tools
Target · 2029
2
Novel protein therapeutics into preclinical validation
Both are goals we aim to reach by 2029. Neither is achieved today, and neither is promised.
FAQ
AI tools for neurological disease diagnosis combined with therapeutic protein design. We have 5 deployed products covering neurology, ENT diagnostics, and drug discovery.
Gachon University, Seongnam-si, South Korea — operating from the Lipid Biochemistry Lab.
Yes! All 5 products are live and publicly accessible. Check the Products section above for direct links.
We are currently in the pre-incorporation phase, planning to incorporate in early 2027. We are actively seeking pilot partners.
Founded by Kartic, a PhD candidate at Gachon University, and advised by Prof. Tae-sik Park, Dean of Research Affairs.
Reach out at [email protected]. We welcome collaborations with university hospitals and biotech companies.
Contact
Interested in a pilot partnership, collaboration, or just want to say hello?
Gachon University, Seongnam-si, South Korea
Lipid Biochemistry Lab, Dept. of Life Science
Ratan Bio is currently in pre-incorporation phase. We are actively seeking pilot partners in Korean university hospitals and biotech companies. If you are interested in collaborating, we would love to hear from you.
Thank you — your message has been sent.
We'll get back to you soon.